Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial

Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial

Hung-Hsien Chiang,1 Deng-Chyang Wu,2 Pin-I Hsu,3 Chao-Hung Kuo,2 Wei-Chen Tai,1 Shih-Cheng Yang,1 Keng-Liang Wu,1 Chih-Chien Yao,1 Cheng-En Tsai,1 Chih-Ming Liang,1 Yao-Kuang Wang,2 Jiunn-Wei Wang,2 Chih-Fang Huang,4 Seng-Kee Chuah,1  on behalf of the Taiwan Acid-Related Disease St...

Full description

Bibliographic Details
Main Authors:	Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM, Wang YK, Wang JW, Huang CF, Chuah SK
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-04-01
Series:	Drug Design, Development and Therapy
Subjects:	Dexlansoprazole Esomeprazole 24 week’s response Complete symptom resolution rate Gastroesophageal reflux disease On-demand GERDQ score
Online Access:	https://www.dovepress.com/clinical-efficacy-of-60-mg-dexlansoprazole-and-40-mg-esomeprazole-afte-peer-reviewed-article-DDDT

Similar Items

The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis
by: Gabriel Pereira Nunes, et al.
Published: (2024-01-01)

Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
by: Mermelstein J, et al.
Published: (2016-07-01)

Comparison of the Effect of Omeprazole, Pantoprazole, Esomeprazole, and Lansoprazole on the Reduction of Symptoms in Patients with Gastroesophageal Reflux Disease
by: Nima Arezoomandi, et al.
Published: (2019-02-01)

Efficacy and Safety of Esomeprazole for the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis
by: Mingxing HOU, et al.
Published: (2020-11-01)

The Effect of Esomeprazole 40 mg Single Therapy in Patients with Non-Erosive Reflux Disease Who Are Resistant to Standard-Dose Proton Pump Inhibitor Therapy: An Open-Label Multicenter Study
by: Jae Kyu Sung, et al.
Published: (2016-12-01)

Therapeutic Response to 20 mg of Esomeprazole Twice Daily in Patients with Gastroesophageal Reflux Disease-related Non-cardiac Chest Pain: An Open-Label Randomized Pilot Study
by: Jae Kyun Choi, et al.
Published: (2020-06-01)

The Effectiveness of Omeprazole and Esomeprazole in Infants (1- 11 Months of Age) with Gastroesophageal Reflux Disease: A Comparative Study
by: Ramin Madani, et al.
Published: (2024-01-01)

Comparison of the Carlsson-Dent and GERD-Q questionnaires for gastroesophageal reflux disease symptom detection in a general population
by: R. Contreras-Omaña, et al.
Published: (2017-01-01)

Prevalence of Gastroesophageal Reflux Disease among Diabetic Patients at Sharif Medical City Hospital, Lahore, Pakistan
by: Syed Muslim Mehdi, et al.
Published: (2023-06-01)

Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole Avaliação clínica e endoscópica da doença do refluxo gastroesofágico em pacientes tratados com esomeprazol
by: Edson Pedro da Silva, et al.
Published: (2003-12-01)

Increase in treatment compliance reveals new options of treatment of gastroesophageal reflux disease
by: Yu. V. Yevsyutina, et al.
Published: (2024-03-01)

Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study
by: Hyun Lim, et al.
Published: (2023-12-01)

Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study
by: Min-Gul Kim, et al.
Published: (2023-01-01)

GASTROESOPHAGEAL REFLUX: NEW THERAPEUTIC PROSPECTS
by: S. S. Kardasheva, et al.
Published: (2017-07-01)

Comparative analysis of the effect of PO administered acid suppressants on gastric pH in healthy cats
by: Phillip Ryan, et al.
Published: (2020-09-01)

Longitudinal study of gastroesophageal reflux and erosive tooth wear
by: Clive H. Wilder-Smith, et al.
Published: (2017-10-01)

The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole
by: El-Dika Samer, et al.
Published: (2005-01-01)

Prevalence of symptoms of gastroesopahgeal reflux in a cohort of Saudi Arabians: A study of 1265 subjects
by: Majid A Almadi, et al.
Published: (2014-01-01)

Options for optimizing treatment of gastroesophageal reflux disease with proton pump inhibitors
by: M. F. Osipenko, et al.
Published: (2015-12-01)

Symptoms, the GerdQ score and patients’ characteristics do not predict gastroesophageal reflux disease in patients with proton-pump-inhibitor-refractory reflux symptoms—results from a large prospective database
by: Joachim Labenz, et al.
Published: (2023-02-01)

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice
by: Hung KT, et al.
Published: (2021-03-01)

A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial
by: Tai WC, et al.
Published: (2019-09-01)

The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease
by: N. V. Topchiy, et al.
Published: (2018-04-01)

EVALUATION OF PSORIASIS TREATMENT WITH ESOMEPRAZOLE - A PILOT STUDY
by: Mauro BAFUTTO, et al.

Esomeprazole-induced lichen planus
by: Miguel Santos-Coelho, et al.
Published: (2023-04-01)

Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects
by: Kim HC, et al.
Published: (2023-04-01)

Preparation and Characterization of Controlled-Release Floating Bilayer Tablets of Esomeprazole and Clarithromycin
by: Muhammad Israr, et al.
Published: (2022-05-01)

Comparison of RDQ and GERDQ for Predicting Erosive Esophagitis in Patients with Typical GERD Symptoms
by: Titong Sugihartono, et al.
Published: (2023-08-01)

Randomized Controlled Trial Comparing the Efficacy of Sustained-Release Formula of Mosapride-Plus-Esomeprazole Combination Therapy to Esomeprazole Monotherapy in Patients with Gastroesophageal Reflux Disease
by: Hye Kyung Jeon, et al.
Published: (2022-04-01)

Treatment of patients with erosive esophagitis. A modern view on the problem
by: S. V. Morozov, et al.
Published: (2018-04-01)

Corrosion mitigation on orthodontic wire made of SS 18/8 alloy using esomeprazole tablet (Esiloc-40 mg) in artificial saliva
by: Akbar A.S. Begum, et al.
Published: (2023-07-01)

Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats
by: Tae Hwan Kim, et al.
Published: (2018-09-01)

Esomeprazole: a Safe Alternative to Lansoprazole Allergy?
by: Muammer Kara, et al.
Published: (2014-08-01)

Influence of the Impregnation Technique on the Release of Esomeprazole from Various Bioaerogels
by: Milica Pantić, et al.
Published: (2021-06-01)

Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs
by: Cook EK, et al.
Published: (2016-08-01)

Preclinical Evaluation of Esomeprazole Safety and Toxicokinetics
by: V. M. Kosman, et al.
Published: (2023-06-01)

Gastroesophageal Reflux Disease
by: Chan Hyuk Park, et al.
Published: (2019-02-01)

Pharmacokinetics and bioequivalence study of esomeprazole magnesium enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions
by: Ying Ding, et al.
Published: (2023-04-01)

Prediction of Drug Stability Using Deep Learning Approach: Case Study of Esomeprazole 40 mg Freeze-Dried Powder for Solution
by: Jovana Ajdarić, et al.
Published: (2021-06-01)

Esomeprazole and apixaban pharmacokinetic interactions in healthy rats
by: Ali Jaber, et al.
Published: (2022-10-01)